Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Perspective Therapeutics, Inc.

Market Cap 340M 295M 272M 256M 479M 32.12B 484M 3.23B 1.25B 15.78B 1.28B 1.25B 54.57B P/E 2026 *
-2.69x
P/E 2027 * -2.63x
Enterprise Value 153M 133M 122M 115M 215M 14.44B 218M 1.45B 563M 7.09B 573M 561M 24.52B EV / Sales 2026 *
366x
EV / Sales 2027 * 56.5x
Free-Float
89.19%
Yield 2026 *
-
Yield 2027 * -
1 day+1.71%
1 week-0.67%
Current month-24.37%
1 month-22.60%
3 months-42.91%
6 months+4.93%
Current year+8.36%
1 week 2.86
Extreme 2.865
3.12
1 month 2.85
Extreme 2.85
4.34
Current year 2.25
Extreme 2.25
6.16
1 year 1.96
Extreme 1.955
6.16
3 years 1.6
Extreme 1.6
19.05
5 years 1.6
Extreme 1.6
19.05
10 years 1.6
Extreme 1.6
28.1
Manager TitleAgeSince
Chief Executive Officer 54 2023-02-04
Director of Finance/CFO 59 2025-09-03
Chief Tech/Sci/R&D Officer - 2022-03-31
Director TitleAgeSince
Director/Board Member 54 2023-02-04
Chairman 63 2023-02-02
Director/Board Member 60 2023-02-04
Date Insider Type Main position Quantity % Market Cap.
03-01Free

Chairman

50,000 0.0439%
03-01Free

Director

50,000 0.0439%
03-01Free

Director

50,000 0.0439%
Change 5-day change 1-year change 3-year change Capi.($)
+1.71%-0.67%-17.45%-57.93% 334M
-0.22%-0.40%-13.00%-13.09% 43.51B
+0.76%+5.50%+296.71%+540.82% 33.29B
-0.47%-2.05%-0.66%+31.20% 29.34B
-4.74%-8.37%+7.17%-20.99% 29.9B
+0.06%+2.71%+13.31%+21.11% 25.42B
-0.02%+8.40% - - 14.36B
-0.98%-2.08%+51.87%+106.06% 13.18B
-0.29%-3.76%+2.12%+1.69% 12.72B
+1.67%-0.36%+110.87%+81.16% 12.08B
Average -0.25%+0.37%+50.10%+76.67% 21.41B
Weighted average by Cap. -0.63%+0.72%+59.51%+103.31%

Financials

2026 *2027 *
Net sales 418K 363K 334K 314K 589K 39.48M 595K 3.97M 1.54M 19.39M 1.57M 1.53M 67.07M 488K 424K 390K 367K 687K 46.08M 695K 4.64M 1.8M 22.63M 1.83M 1.79M 78.28M
Net income -121M -105M -96.71M -90.96M -171M -11.43B -172M -1.15B -446M -5.62B -454M -444M -19.42B -138M -120M -110M -104M -195M -13.06B -197M -1.31B -509M -6.41B -518M -507M -22.18B
Net Debt -187M -163M -150M -141M -264M -17.69B -267M -1.78B -690M -8.69B -702M -687M -30.04B -312M -271M -250M -235M -440M -29.52B -445M -2.97B -1.15B -14.5B -1.17B -1.15B -50.14B
Logo Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. It is also developing imaging diagnostics that incorporate the same targeting moieties, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Employees
165
Date Price Change Volume
26-06-17 2.980 $ +1.71% 2,046,519
26-06-16 2.930 $ -0.34% 765,604
26-06-15 2.940 $ -0.34% 1,758,437
26-06-12 2.950 $ -0.67% 1,027,229
26-06-11 2.970 $ +0.68% 1,052,849
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.980USD
Average target price
12.93USD
Spread / Average Target
+334.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CATX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!